Top Page
Pharmaust Limited
(Sydney:NUZ)
Pharmaust Limited (NUZ) vs. iShares MSCI Australia ETF (EWA)
Pharmaust Limited Business Overview & Revenue Model
Pharmaust Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 857.35K | 0.00 | 0.00 | 2.82M | 3.38M | 3.38M |
| Gross Profit | 855.71K | 0.00 | -1.64K | -929.53K | -223.52K | 3.07M |
| EBITDA | -9.45M | -18.48M | -9.45M | -9.45M | -1.30M | -1.30M |
| Net Income | -7.69M | -16.59M | -9.03M | -9.03M | -1.71M | -1.71M |
Balance Sheet | ||||||
| Total Assets | 11.12M | 4.36M | 11.12M | 6.13M | 6.13M | 10.08M |
| Cash, Cash Equivalents and Short-Term Investments | 9.72M | 4.18M | 9.72M | 2.71M | 2.71M | 3.02M |
| Total Debt | 0.00 | 0.00 | 0.00 | 1.05M | 1.05M | 1.28M |
| Total Liabilities | 896.61K | 1.54M | 896.61K | 2.24M | 2.23M | 2.23M |
| Stockholders Equity | 10.23M | 2.82M | 10.23M | 3.89M | 7.84M | 8.88M |
Cash Flow | ||||||
| Free Cash Flow | -5.17M | -14.29M | -5.17M | -1.60M | -1.38M | -1.08M |
| Operating Cash Flow | -5.17M | -14.29M | -5.17M | -1.56M | -1.33M | -937.97K |
| Investing Cash Flow | -1.17M | -21.55K | -1.17M | -34.93K | -43.38K | -138.04K |
| Financing Cash Flow | 13.34M | 8.76M | 13.34M | 1.89M | 770.99K | 1.22M |
Pharmaust Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$94.16M | -14.80 | -47.98% | ― | 700.00% | 26.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$66.25M | -5.28 | -49.72% | ― | ― | 10.78% | |
42 Neutral | AU$57.99M | -4.29 | -247.98% | ― | ― | ― | |
41 Neutral | AU$130.13M | -2.84 | ― | ― | ― | 0.66% |
Pharmaust Limited Corporate Events
Neurizon Therapeutics has drawn down the first $5 million tranche of its previously announced $20 million strategic convertible note facility with Obsidian Global GP, providing immediate funding support for its clinical programs. The financing underscores Neurizon’s focus on advancing NUZ-001, its lead ALS candidate, and strengthens its cash position as it progresses through key development milestones.
Proceeds from the initial tranche will fund Neurizon’s participation in the HEALEY ALS Platform Trial, an adaptive Phase 2/3 registrational study evaluating NUZ-001 in patients with amyotrophic lateral sclerosis. The drawdown coincides with first patient dosing in the trial, marking the transition into an active dosing and data generation phase, while the remaining $15 million facility offers funding flexibility to support clinical execution, manufacturing readiness and broader corporate initiatives.
Neurizon plans to deploy capital in a disciplined, milestone-driven manner as it advances its development pipeline and prepares for potential future commercialisation activities. The strategic financing and clinical progress enhance the company’s position in the competitive neurodegenerative disease space and have implications for investors and other stakeholders monitoring its ability to deliver value through successful trial outcomes and operational execution.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.28 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has issued a cleansing notice ahead of the expected issuance of 3,575,500 unquoted convertible notes to New York-based Obsidian Global GP under a two-year, up to A$20 million funding facility. The first A$5 million drawdown will increase Neurizon’s cash reserves while also raising its secured indebtedness, with the notes convertible into fully paid ordinary shares, implying future equity dilution but providing immediate funding flexibility for ongoing operations.
The company confirms shareholder approval for the first tranche and indicates that remaining conditions precedent for the issue are either satisfied or will be met on the day of issuance. Upon conversion of the notes, Neurizon’s share count will rise and its debt will fall by the face value of notes converted, shaping its capital structure and giving the company scope to manage liquidity and balance-sheet strength as it progresses its activities.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has issued 10,000,000 fully paid ordinary shares to Obsidian Global GP, LLC under a previously approved convertible note facility, following shareholder approval at a recent general meeting. The company confirmed the shares were issued without a prospectus under the Corporations Act disclosure exemptions, stated it is up to date with its financial reporting and continuous disclosure obligations, and advised that there is no excluded information, helping to provide regulatory clarity and maintain investor confidence around the capital raising.
Neurizon also highlighted the availability of its dedicated Investor Hub, designed to centralise communication with shareholders through Q&A, feedback, and video summaries of key announcements. This initiative supports greater transparency and engagement with investors as the company advances its clinical programs and deploys new capital from the share issuance to fund its neurodegenerative disease pipeline.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has begun dosing the first participant with its lead candidate NUZ-001 in Regimen I of the HEALEY ALS Platform Trial, a multicentre adaptive Phase 2/3 study run by the Sean M. Healey & AMG Center for ALS at Mass General Brigham. The trial will enrol about 160 ALS patients across more than 70 U.S. sites in a 36-week randomised, double-blind, placebo-controlled design to evaluate NUZ-001’s impact on disease progression and safety.
Entry into the highly competitive HEALEY platform gives Neurizon access to an established clinical framework, top-tier ALS investigators and streamlined infrastructure, positioning this study as the company’s potential registrational trial to support future regulatory submissions. The move follows a small Phase 1 program that showed encouraging preliminary efficacy and a favourable safety profile, marking a significant milestone in Neurizon’s bid to advance NUZ-001 as a new therapy option in a disease area with high unmet need.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited reported a sharply lower half-year loss for the period ended 31 December 2025, with the deficit narrowing 23.9% to $5.54 million as other income surged 241.5% to nearly $6.0 million. The company’s balance sheet strengthened significantly, with net assets rising to $8.29 million and net tangible assets per share almost tripling to 1.55 cents, although it continues to forgo dividends as it prioritises funding ongoing development activities.
The improved financial metrics highlight enhanced capital backing and operational runway for Neurizon, factors that may offer greater resilience in a capital-intensive therapeutic development environment. However, the continued absence of dividends underscores its early-stage, growth-focused profile, leaving investors primarily exposed to the long-term success of its research pipeline rather than near-term income returns.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has released the results of its general meeting, disclosing details of the resolutions considered and proxy votes received, as required under Australian corporate and listing rules. The company also directed investors to its dedicated Investor Hub, which offers a central platform for questions, comments, and video summaries of key announcements, underscoring its emphasis on transparency and engagement with stakeholders.
By formally reporting voting outcomes and promoting its Investor Hub, Neurizon reinforces its governance practices and maintains communication channels with both Australian and U.S. investors. This approach supports the company’s positioning as a compliant, investor-focused biotech as it advances NUZ-001 through clinical development in the competitive neurodegenerative disease arena.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has released a general meeting presentation outlining information for shareholders while stressing that the material should not be regarded as financial, legal, tax or investment advice. The company emphasises that the presentation is incomplete as an investment basis, may be updated at its discretion and that investors must conduct their own due diligence.
The release highlights extensive disclaimers around the accuracy and completeness of the information, noting that no warranties are given and liability is expressly limited to the maximum extent permitted by law. It also underscores that references to future intentions, plans and strategies are subject to significant risks and uncertainties, and cautions investors not to place undue reliance on forward-looking statements.
Neurizon further advises that its securities are not registered in the United States and cannot be offered or sold there or to U.S. persons without appropriate registration or exemption. The overall message positions the presentation as informational only, clearly distinguishing it from any offer of securities and reinforcing strict compliance with Australian and U.S. securities regulations.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics director Marcus Hughes has increased his equity stake in the company through the on-market purchase of 750,000 fully paid ordinary shares at $0.08 per share, for a total consideration of $60,000. Following the transaction, Hughes directly holds 13,110,746 fully paid ordinary shares and 600,000 unlisted options exercisable at $0.20 each by 30 June 2032, in addition to indirect holdings via a family superannuation fund and his spouse, signalling continued personal financial commitment and alignment of interests with other shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.28 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon reported a pivotal quarter marked by the US FDA lifting the clinical hold on NUZ-001’s IND and subsequently clearing the drug to enter the HEALEY ALS Platform Trial as Regimen I, positioning the asset at the centre of global ALS drug development and de-risking its path toward late-stage clinical evaluation. The company advanced manufacturing readiness with successful registration batches, strengthened long-term IP protection with a new Australian patent extending coverage for NUZ-001 to 2041, broadened its capital markets reach via OTCQB listing and US investor relations support, and secured a comprehensive funding package—combining placements, a strategic convertible note facility and an entitlement offer—alongside an R&D tax rebate to fully fund both phases of the HEALEY ALS Platform Trial and reinforce its balance sheet heading into 2026.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has secured a A$6.0 million cash rebate under the Australian Government’s R&D Tax Incentive program for FY2025, reflecting a 48.5% rebate on eligible domestic and overseas R&D activities, supported by an Advance & Overseas Finding that extends through FY2027. After repaying a previously arranged A$1.5 million R&D financing facility with Radium Capital, the company receives about A$4.35 million in net cash, which will be directed to fund its participation in the HEALEY ALS Platform Trial and support broader clinical development and commercialisation readiness for NUZ-001, reinforcing its non-dilutive funding strategy and strengthening its competitive position as an Australian-based neurodegenerative drug developer.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has applied for quotation on the ASX of 73,508,717 new ordinary fully paid shares under the code NUZ, with an issue date of 29 January 2026, following previously announced transactions. The substantial new share issuance increases the company’s quoted capital base and may enhance its liquidity and financial flexibility, potentially supporting ongoing development programs and strengthening its position within the competitive therapeutics sector, while existing shareholders will need to assess the implications of the expanded share register on ownership dilution and market valuation.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has raised approximately $5.88 million through a well-supported pro-rata non-renounceable entitlement offer, issuing around 73.5 million new shares at $0.08 each, including strong oversubscription demand from eligible shareholders. The proceeds bolster the company’s balance sheet and provide additional flexibility to fund regulatory, manufacturing and operational activities tied to advancing its lead candidate NUZ-001 in the HEALEY ALS Platform Trial, where Neurizon remains fully funded to complete participation and is targeting first patient dosing in the first quarter of calendar 2026; the company also retains discretion to place a substantial shortfall of shares within three months, which could further support its clinical development strategy and broaden its shareholder base.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has reported a change in the holdings of director Dr Michael Thurn, who maintains both direct and indirect interests in the company through family accounts and personal holdings of shares, options and performance rights. The notice confirms the lapse or disposal of 1,000,000 unlisted options expiring on 19 January 2026 at $0.175, with no consideration received, leaving Dr Thurn’s remaining interests concentrated in fully paid ordinary shares, listed options, longer-dated unlisted options and performance rights, and signalling a modest simplification of his short‑dated derivative exposure without altering his substantial alignment with shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has called a virtual-only General Meeting of shareholders for 20 February 2026 at 2:00pm AEDT, to be held via an online meeting platform, with all meeting materials, including the Notice of Meeting and explanatory statement, provided electronically through the company’s website, share registry portal, and ASX announcements page. The move underscores Neurizon’s shift away from physical mailouts toward digital communication, streamlining shareholder engagement and voting processes while encouraging investors to update their communication preferences, submit proxies ahead of the meeting, and utilise online channels for access and participation, which may enhance accessibility and reduce administrative costs for the company and its stakeholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has secured registered trademark protection for the NEURIZON brand across its key global commercial markets, including the United States, European Union, United Kingdom, Australia and Japan, covering pharmaceutical research and development, clinical trial services and neurological therapeutics. The completion of this global trademark portfolio, particularly the US registration in Neurizon’s primary long-term commercialisation market, strengthens the company’s intellectual property framework alongside patent protection for lead asset NUZ-001, supports consistent global brand deployment and enhances strategic flexibility for future partnerships or independent commercialisation as it advances towards later-stage clinical development.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has released an investor webinar presentation outlining recent strategic and operational progress, including a strengthened funding position, regulatory developments and preparations to commence patient enrolment in the HEALEY ALS Platform Trial. The presentation details the company’s clinical strategy for lead asset NUZ-001, key near-term milestones and execution priorities for calendar year 2026, signalling an important phase of clinical and corporate execution that could influence its positioning in the ALS treatment landscape and its engagement with existing and prospective investors.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has scheduled a shareholder webinar for 15 January 2026 to brief investors on the execution of recent funding initiatives, regulatory developments and upcoming operational milestones related to its participation in the HEALEY ALS Platform Trial. The event, led by CEO and Managing Director Dr Michael Thurn and other team members, will include a Q&A session, require prior registration, and will be recorded for later viewing, underscoring the company’s effort to increase transparency and engagement with investors as it advances its lead ALS drug candidate through key clinical and regulatory inflection points.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has reported the expiry of 3 million unlisted options exercisable at $0.15 that were due to lapse on 31 December 2025, with none of these options being exercised before their expiry. The cessation of these securities reduces the pool of potential future share dilution for existing investors and marginally simplifies the company’s capital structure, though it does not immediately alter the number of shares on issue or directly affect day-to-day operations.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has opened a pro-rata non-renounceable entitlement offer to raise up to approximately A$17.1 million before costs, giving eligible shareholders the right to subscribe for two new shares for every five held at an offer price of A$0.08 per share, based on a record date of 30 December 2025. The capital raising, which runs from 5 to 21 January 2026 under an ASX-compliant timetable, is expected to bolster the company’s funding base as it advances clinical development of its ALS candidate NUZ-001 and supports its broader ambitions in neurodegenerative disease, with the structure of the offer providing existing investors an opportunity to maintain their ownership position.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has issued 79,330,864 fully paid ordinary shares at $0.08 per share to sophisticated and professional investors under a placement first announced in late December 2025. The company has confirmed the shares were issued without a prospectus under the Corporations Act’s cleansing provisions and that it remains compliant with its continuous disclosure and financial reporting obligations, with no excluded information outstanding, effectively clearing the way for secondary trading of the new stock and reinforcing regulatory transparency for shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has provided a regulatory update on NUZ-001, its investigational ALS therapy, confirming that the US FDA has declined its initial Fast Track Designation request but offered detailed feedback on the additional clinical data needed to demonstrate differentiation from existing approved treatments. The company views this as a clear regulatory pathway and plans to generate the requested evidence as NUZ-001 progresses, potentially enabling a renewed Fast Track application and influencing its long-term positioning in the competitive ALS drug development landscape.
Operationally, NUZ-001 has advanced within the HEALEY ALS Platform Trial into key start-up phases, with IRB submissions, site activations and related activities underway, and first patient enrolment expected very early this year, underpinned by recently secured funding sufficient to complete the pivotal registration-adaptive Phase 2/3 study. Participation in the large, multicentre HEALEY platform, designed to accelerate ALS drug development via shared infrastructure and adaptive trial design, gives Neurizon an efficient route to generate robust clinical data, which is critical for future regulatory interactions and value creation for patients, investors and partners.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has disclosed a change in director Sergio Duchini’s interests, with Duchini, through Kelbury Pty Ltd, acquiring 416,667 fully paid ordinary shares at $0.12 per share in a recent placement. Following the transaction, his indirect holding increased to 1,732,456 shares while his direct holding of 960,000 unlisted options remained unchanged, signalling continued insider support for the company’s capital raising efforts and potentially reinforcing market confidence in its strategic direction.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has applied to the ASX for quotation of 79,330,864 new ordinary fully paid shares, to be issued on 2 January 2026 under code NUZ. The application, lodged as an Appendix 2A, indicates a significant expansion of the company’s quoted share capital, which may influence market liquidity and ownership structure and is linked to transactions previously flagged in an earlier Appendix 3B filing.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has issued 1,083,335 fully paid ordinary shares to participating directors from its September 2025 placement at $0.12 per share, following shareholder approval at the company’s November 2025 annual general meeting. The company confirmed the shares were issued without a prospectus under the Corporations Act cleansing provisions and stated it is up to date with its financial reporting and continuous disclosure obligations, with no excluded information, ensuring the new securities can trade freely and signaling continued alignment between the board and shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has launched a pro-rata non-renounceable entitlement offer to raise up to approximately $17.1 million before costs, giving eligible shareholders the right to subscribe for two new shares for every five held at an issue price of $0.08 per share, based on a record date of 30 December 2025. The offer will be conducted without a prospectus under Australia’s cleansing notice provisions, with the company confirming compliance with continuous disclosure obligations and stating that, given the pro-rata structure and current substantial holdings, the capital raising is not expected to have any material impact on the control of the company, thereby providing additional funding with limited governance disruption for existing investors.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has announced a proposed capital raising involving the issue of up to 3,314,000 convertible notes and 25,000,000 new fully paid ordinary shares via a placement or similar structure. The proposed issuance, scheduled for 17 February 2026, is designed to strengthen the company’s balance sheet and provide funding flexibility for its therapeutic development programs, potentially diluting existing shareholders but supporting Neurizon’s ability to advance its pipeline and maintain its position in the competitive biotech market.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has announced a proposed non-renounceable pro rata issue of up to 214,315,640 new ordinary fully paid shares, alongside a separate placement or other type of issue of up to 89,080,864 shares, as part of a broader capital-raising initiative. The staged timetable, with key dates spanning late December 2025 to late January 2026, signals a substantial expansion of the company’s equity base, which may provide additional funding capacity for its therapeutic programs while diluting existing holdings, and underscores management’s reliance on the equity markets to support ongoing development and growth plans.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has launched an equity raising comprising a placement of new fully paid ordinary shares to eligible institutional, sophisticated and professional investors, alongside a non-renounceable entitlement offer of new shares to existing eligible shareholders. The offer, which is not underwritten and may be varied or withdrawn at the company’s discretion, is being managed by Morgans Corporate Limited and includes the potential placement of any shortfall shares within three months of the entitlement offer’s close, with allocations determined by Neurizon to support an informed and liquid trading market and a broad, long-term shareholder base.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has secured a comprehensive funding package to support its participation in the HEALEY ALS Platform Trial for its lead drug candidate NUZ-001, a pivotal adaptive Phase 2/3 registration study in ALS. The package comprises approximately $7.1 million raised via a discounted share placement to new and existing sophisticated investors, a proposed 2-for-5 non-renounceable entitlement offer to raise up to a further $17.1 million, and a $20 million convertible note facility from New York-based Obsidian Global GP, structured to provide milestone-aligned capital over two years while limiting upfront dilution. Together with existing cash and expected R&D tax rebates, the funding underpins both the randomized and extension phases of the HEALEY trial and extends Neurizon’s capital runway, enabling it to advance NUZ-001 through late-stage clinical development, pursue accelerated regulatory pathways, build broader commercial and partnering opportunities, and explore the drug’s potential as a platform therapy across multiple neurodegenerative indications, which management says fundamentally strengthens the company’s balance sheet and long-term value proposition for shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics has requested and been granted a trading halt on its ordinary shares and listed options on the ASX, effective from 19 December 2025, as it prepares to announce the outcome of a proposed capital raising. The halt, which is intended to help the company manage its continuous disclosure obligations, will remain in place until either the announcement is released or normal trading resumes on 23 December 2025, signaling that a potentially significant funding development is imminent for investors and other stakeholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has announced that the US FDA has cleared its drug regimen, NUZ-001, for entry into the HEALEY ALS Platform Trial. This clearance marks a significant regulatory milestone for Neurizon, allowing the company to proceed with clinical activities aimed at developing a new treatment for ALS. The trial, which is a multicenter, double-blind, placebo-controlled, adaptive trial, aims to accelerate the development of potential new ALS therapies. The clearance is expected to enhance Neurizon’s position in the industry and bring it closer to addressing the unmet medical needs of ALS patients.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
Neurizon Therapeutics Limited has amended its Constitution following approval by shareholders at the Annual General Meeting. This amendment aligns with the company’s strategic focus on advancing treatments for neurodegenerative diseases, potentially impacting its operations and positioning within the biotech industry. The changes reflect Neurizon’s commitment to enhancing its governance framework as it continues to develop innovative therapies for ALS and other neural disorders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.